亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會(huì)員登錄|免費(fèi)注冊(cè)|忘記密碼|管理入口 返回主站||保存桌面|手機(jī)瀏覽|聯(lián)系方式|購(gòu)物車
企業(yè)會(huì)員第1年

武漢楷倫化學(xué)新材料有限公司市場(chǎng)  

比馬前列素 阿瑞匹坦及中間體 亞硝基過***鉀 埃索美拉唑鈉及中間體 CB-03-1

搜索
新聞中心
  • 暫無新聞
產(chǎn)品分類
聯(lián)系方式
  • 聯(lián)系人:江君
  • 電話:027-87773372
  • 郵件:2513471628@qq.com
  • QQ:2513471628
站內(nèi)搜索
 
榮譽(yù)資質(zhì)
  • 暫未上傳
友情鏈接
  • 暫無鏈接
右旋蘭索拉唑
單價(jià) 面議對(duì)比
詢價(jià) 暫無
發(fā)貨 湖北武漢市付款后3天內(nèi)
過期 長(zhǎng)期有效
更新 2019-06-28 09:56
 
詳細(xì)信息
 右旋蘭索拉唑
中文名稱: 右旋蘭索拉唑
中文同義詞: (R)-蘭索拉唑;2-[[3-甲基-4-(2,2,2-三氟乙氧基)吡啶-2-基]甲基亞磺酰基]-1H-苯并咪唑;右蘭索拉唑;右旋蘭索拉唑;蘭索拉唑R-異構(gòu)體;右蘭索拉唑相關(guān)雜質(zhì)2;蘭索拉唑雜質(zhì) 11;右旋蘭索拉唑 138530-94-6
英文名稱: R-(+)-Lansoprazole
英文同義詞: (R)-2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole;1H-Benzimidazole, 2-[(R)-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI);1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-, (R)-;R-(+)-Lansoprazole;Dexlansoprazole;2-[(R)-[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole;T 168390;TAK 390
CAS號(hào): 138530-94-6
分子式: C16H14F3N3O2S
分子量: 369.36
EINECS號(hào): 1308068-626-2
 
©2025 武漢楷倫化學(xué)新材料有限公司市場(chǎng) 版權(quán)所有   技術(shù)支持:化工網(wǎng)   訪問量:10628  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |